Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges

通过癌症重大挑战项目资助的Akoya技术，用于生成首个生物样本库和数据存储库的数据，以促进癌症公平研究。

initiative

主动性

The unprecedented scale of the initiative requires the high plex and high throughput of Akoya’s PhenoCycler-Fusion platform to process thousands of patients' samples

该计划的规模空前，需要 Akoya 的 PhenoCycler-Fusion 平台具备高复杂性和高通量来处理成千上万名患者的样本。

MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research..

马萨诸塞州马尔伯勒，2025年4月2日（环球新闻社）——Akoya Biosciences, Inc.（纳斯达克股票代码：AKYA），空间生物学公司®，与由癌症重大挑战计划资助的SAMBAI团队今天宣布，Akoya的PhenoCycler-Fusion系统将成为用于为首个生物样本库和数据存储库生成数据的基础空间蛋白质组学技术，致力于癌症公平研究。

SAMBAI, which stands for “Societal, Ancestry, Molecular and Biological Analyses of Inequalities,” explains this team’s overarching objective to understand the mechanisms and contributions of genetics, biology, environmental, and social determinants to cancer risk and outcomes in diverse populations, and to provide foundational knowledge for developing novel approaches to reduce cancer inequities..

“SAMBAI”代表“社会、祖先、分子和生物学不平等分析”，该团队的总体目标是理解遗传学、生物学、环境和社会决定因素对不同人群癌症风险和结果的机制与贡献，并为开发减少癌症不平等的新方法提供基础知识。

Team SAMBAI will focus on assessing disparate cancer outcomes in 40,000 individuals of African descent from Africa, the UK and the US and include proteomics, transcriptomics, and other data types. Teams from Johns Hopkins University, Nottingham University, Glasgow University, and King’s College London will run thousands of samples on the PhenoCycler-Fusion system using panels designed to study breast, pancreatic and prostate cancers – three cancers that have a disproportionately higher rate of aggressive tumor grade and early onset in the target population..

团队SAMBAI将专注于评估来自非洲、英国和美国的40,000名非洲裔个体在癌症结果上的差异，并纳入蛋白质组学、转录组学和其他数据类型。约翰霍普金斯大学、诺丁汉大学、格拉斯哥大学和伦敦国王学院的团队将使用设计用于研究乳腺癌、胰腺癌和前列腺癌的面板，在PhenoCycler-Fusion系统上运行数千个样本——这三种癌症在目标人群中具有不成比例的高侵袭性肿瘤等级和早期发病特点。

“We are excited that the PhenoCycler-Fusion is the spatial proteomics technology of choice for analyzing thousands of patient samples as part of this important initiative,” said Brian McKelligon, CEO of Akoya Biosciences. “A study of this size demands the high plex and high throughput of our solutions to generate data at the scale needed.

“我们很高兴PhenoCycler-Fusion作为这项重要计划的一部分，成为分析数千个患者样本的空间蛋白质组学技术之选，”Akoya Biosciences首席执行官Brian McKelligon表示。“如此规模的研究需要我们的解决方案提供高重数和高通量，以生成所需规模的数据。”

We are honored to play a role in defining the factors that influence disparate outcomes in underserved populations.”.

我们很荣幸能在定义影响服务不足人群不同结果的因素方面发挥作用。

Cancer Grand Challenges identifies cancer’s toughest challenges and funds global research teams with the greatest potential to advance cancer research and improve outcomes for people affected by cancer. Team SAMBAI will receive up to $25 million from Cancer Grand Challenges to develop the project.

Cancer Grand Challenges 识别癌症最严峻的挑战，并资助具有最大潜力推动癌症研究和改善癌症患者预后的全球研究团队。SAMBAI 团队将获得 Cancer Grand Challenges 高达 2500 万美元的资助以推进该项目。

“As a leader in the spatial biology field, Akoya offers the best technology to assess the effect of environmental and societal factors on biology at the molecular level and on the development of cancer at the scale required for this project,” said Melissa Davis, PhD, Director of the Institute of Translational Genomic Medicine at Morehouse School of Medicine and leader of team SAMBAI.

“作为空间生物学领域的领导者，Akoya 提供了最佳技术，可以在分子水平上评估环境和社会因素对生物学的影响，并在该项目所需的规模上研究癌症的发展，”莫尔豪斯医学院转化基因组医学研究所主任、SAMBAI 团队负责人 Melissa Davis 博士说道。

“For the first time in a large population, we plan to bring all of these factors together to understand their interconnectedness and contribution to disparities in health outcomes.”.

“在一个大规模人群中，我们计划首次将所有这些因素综合起来，以理解它们的相互关联性以及对健康结果差异的影响。”

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding the potential of our products and services..

本新闻稿包含基于管理层信念、假设以及管理层目前掌握信息的前瞻性陈述。本新闻稿中所有非历史事实的陈述均为前瞻性陈述，包括关于我们产品和服务潜力的陈述。

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

在某些情况下，您可以通过“可能”、“将”、“可以”、“会”、“应该”、“预期”、“打算”、“计划”、“预计”、“相信”、“估计”、“预测”、“展望”、“潜在”、“持续”、“进行中”等词语或这些词语的否定形式或其他类似术语来识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些词语。

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time.

这些声明涉及可能导致实际结果、活动水平、表现或成就与这些前瞻性声明明示或暗示的信息有重大差异的风险、不确定性和其他因素。这些风险、不确定性和其他因素在我们不时向证券交易委员会提交的文件中的“风险因素”、“管理层对财务状况和经营结果的讨论与分析”以及其它部分有所描述。

We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof.

我们提醒您，前瞻性陈述是基于我们目前已知的事实和因素以及我们对未来的预测，而这些预测并不确定。因此，前瞻性陈述可能最终被证明不准确。本新闻稿中的前瞻性陈述仅代表我们截至本日期的观点。

We undertake no obligation to update any forward-looking statements for any reason, except as required by law..

我们不承担因任何原因更新任何前瞻性陈述的义务，除非法律要求。

About Akoya Biosciences

关于Akoya生物科学公司

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy.

作为空间生物学公司®，Akoya Biosciences的使命是通过空间表型分析的力量为生物学和人类健康领域带来背景信息。该公司提供全面的单细胞成像解决方案，使研究人员能够以空间背景对细胞进行表型分析，并可视化它们如何组织和相互作用以影响疾病进展和治疗反应。

Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit .

Akoya 提供完整的空间表型分析解决方案，以满足研究人员在发现、转化和临床研究中的多样化需求：PhenoCode™ 面板、PhenoCycler®、PhenoImager® Fusion 和 PhenoImager HT 仪器。欲了解有关 Akoya 的更多信息，请访问 。

www.akoyabio.com

www.akoyabio.com

.

。

Investor Contact:

投资者联系方式：

Priyam Shah

普里亚姆·沙阿

investors@akoyabio.com

投资者@akoyabio.com

Media Contact:

媒体联系人：

Ritu Mihani

里图·米哈尼

media@akoyabio.com

媒体@akoyabio.com